Figure 4.

Inhibition of ADCC with normal IgG is glycoform-dependent. (A) Influence of fucosylation of normal IgG on inhibition of ADCC was examined by titration of fucosylation levels of sialylated glycoforms (left) and galactosylated glycoforms (right) at the final concentration of 0.2 mg/ml. Error bars, mean ± S.E. (n = 3). (B) Influence of the IgG glycoforms on inhibition of ADCC was examined at 0.1 mg/ml of each IgG glycoform. Error bars, mean ± S.E. (n = 3). Note that the differences in EC₅₀ between the (G2)₂ and other glycoforms were significant (asterisks) for both FcγRIIIa V158 and F158 (p < 0.01) as determined by extra sum of squares F-test. (C) Titration of the IgG glycoforms for comparison of the ADCC inhibitory capability at 0.1 μg/ml rituximab. Error bars, mean ± S.E. (n = 3). *p < 0.05.